<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30053332</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1349-7006</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>109</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer science</Title>                <ISOAbbreviation>Cancer Sci.</ISOAbbreviation>            </Journal>            <ArticleTitle>Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.</ArticleTitle>            <Pagination>                <MedlinePgn>3149-3158</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.13752</ELocationID>            <Abstract>                <AbstractText>The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has shown dramatic effects in patients with non-small cell lung cancer (NSCLC) harboring ROS1 fusion genes. However, patients inevitably develop resistance to this agent. Therefore, a new treatment strategy is required for lung tumors with ROS1 fusion genes. In the present study, lung cancer cell lines, HCC78 harboring SLC34A2-ROS1 and ABC-20 harboring CD74-ROS1, were used as cell line-based resistance models. Crizotinib-resistant HCC78R cells were established from HCC78. We comprehensively screened the resistant cells using a phosphor-receptor tyrosine kinase array and RNA sequence analysis by next-generation sequencing. HCC78R cells showed upregulation of HB-EGF and activation of epidermal growth factor receptor (EGFR) phosphorylation and the EGFR signaling pathway. Recombinant HB-EGF or EGF rendered HCC78 cells or ABC-20 cells resistant to crizotinib. RNA sequence analysis by next-generation sequencing revealed the upregulation of AXL in HCC78R cells. HCC78R cells showed marked sensitivity to EGFR-TKI or anti-EGFR antibody treatment in vitro. Combinations of an AXL inhibitor, cabozantinib or gilteritinib, and an EGFR-TKI were more effective against HCC78R cells than monotherapy with an EGFR-TKI or AXL inhibitor. The combination of cabozantinib and gefitinib effectively inhibited the growth of HCC78R tumors in an in vivo xenograft model of NOG mice. The results of this study indicated that HB-EGF/EGFR and AXL play roles in crizotinib resistance in lung cancers harboring ROS1 fusions. The combination of cabozantinib and EGFR-TKI may represent a useful alternative treatment strategy for patients with advanced NSCLC harboring ROS1 fusion genes.</AbstractText>                <CopyrightInformation>Â© 2018 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kato</LastName>                    <ForeName>Yuka</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ninomiya</LastName>                    <ForeName>Kiichiro</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ohashi</LastName>                    <ForeName>Kadoaki</ForeName>                    <Initials>K</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5180-3933</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tomida</LastName>                    <ForeName>Shuta</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biobank, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Makimoto</LastName>                    <ForeName>Go</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Watanabe</LastName>                    <ForeName>Hiromi</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kudo</LastName>                    <ForeName>Kenichiro</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Matsumoto</LastName>                    <ForeName>Shingo</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Umemura</LastName>                    <ForeName>Shigeki</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goto</LastName>                    <ForeName>Koichi</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ichihara</LastName>                    <ForeName>Eiki</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ninomiya</LastName>                    <ForeName>Takashi</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kubo</LastName>                    <ForeName>Toshio</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sato</LastName>                    <ForeName>Akiko</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hotta</LastName>                    <ForeName>Katsuyuki</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Innovative Clinical Oncology, Okayama University Hospital, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tabata</LastName>                    <ForeName>Masahiro</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Toyooka</LastName>                    <ForeName>Shinichi</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7588-6745</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maeda</LastName>                    <ForeName>Yoshinobu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kiura</LastName>                    <ForeName>Katsuyuki</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>KAKEN 26893155</GrantID>                    <Agency>JSPS Grants-in-Aid for Scientific Research</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>KAKEN 16K19454</GrantID>                    <Agency>JSPS Grants-in-Aid for Scientific Research</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>KAKEN 15H04830</GrantID>                    <Agency>JSPS Grants-in-Aid for Scientific Research</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>Lung Cancer Research, Japan Lung Cancer Society</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cancer Sci</MedlineTA>            <NlmUniqueID>101168776</NlmUniqueID>            <ISSNLinking>1347-9032</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000813">Anilides</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000944">Antigens, Differentiation, B-Lymphocyte</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C587883">HBEGF protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D066257">Heparin-binding EGF-like Growth Factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C493557">SLC34A2 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D050614">Sodium-Phosphate Cotransporter Proteins, Type IIb</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C045084">invariant chain</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>1C39JW444G</RegistryNumber>                <NameOfSubstance UI="C558660">cabozantinib</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>53AH36668S</RegistryNumber>                <NameOfSubstance UI="C551994">crizotinib</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C062333">ROS1 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C071031">axl receptor tyrosine kinase</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>S65743JHBS</RegistryNumber>                <NameOfSubstance UI="C419708">gefitinib</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Rev Anticancer Ther. 2012 Apr;12(4):447-56</RefSource>                <PMID Version="1">22500682</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Mar 10;30(8):863-70</RefSource>                <PMID Version="1">22215748</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 2014 May;27(5):711-20</RefSource>                <PMID Version="1">24186139</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Dec 15;22(24):5983-5991</RefSource>                <PMID Version="1">27401242</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 May 15;22(10):2351-8</RefSource>                <PMID Version="1">26673800</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2017 Jul 1;77(13):3551-3563</RefSource>                <PMID Version="1">28428274</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Mar 15;22(6):1313-7</RefSource>                <PMID Version="1">26763248</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2016 Dec;17(12):1653-1660</RefSource>                <PMID Version="1">27825636</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2011 Dec;10(12):2298-308</RefSource>                <PMID Version="1">21926191</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2017 Aug;16(8):1623-1633</RefSource>                <PMID Version="1">28500237</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Med. 2012 Feb 12;18(3):378-81</RefSource>                <PMID Version="1">22327623</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2018 Oct;109(10):3149-3158</RefSource>                <PMID Version="1">30053332</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2016 Apr 28;59(8):3593-608</RefSource>                <PMID Version="1">26555154</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2013 Jun 20;368(25):2395-401</RefSource>                <PMID Version="1">23724914</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Mar 10;31(8):1070-80</RefSource>                <PMID Version="1">23401451</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2016 Dec;17(12):1661-1671</RefSource>                <PMID Version="1">27825638</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2016 Aug;11(8):1273-1281</RefSource>                <PMID Version="1">27068398</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19519-24</RefSource>                <PMID Version="1">24218589</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2015 Jan 1;21(1):166-74</RefSource>                <PMID Version="1">25351743</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2018 May 10;36(14):1405-1411</RefSource>                <PMID Version="1">29596029</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2014 Nov 20;371(21):1963-71</RefSource>                <PMID Version="1">25264305</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2018 Jul 15;24(14):3334-3347</RefSource>                <PMID Version="1">29636358</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2015 May 15;21(10):2379-87</RefSource>                <PMID Version="1">25688157</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol Methods. 1983 Dec 16;65(1-2):55-63</RefSource>                <PMID Version="1">6606682</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8</RefSource>                <PMID Version="1">25733882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2016 Apr;107(4):461-8</RefSource>                <PMID Version="1">26845230</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Genet. 2012 Jul 01;44(8):852-60</RefSource>                <PMID Version="1">22751098</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2017 Aug 10;35(23):2595-2597</RefSource>                <PMID Version="1">28520528</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2012 Sep 1;18(17):4570-9</RefSource>                <PMID Version="1">22919003</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2014 May 21;311(19):1998-2006</RefSource>                <PMID Version="1">24846037</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2018 Apr;13(4):e66-e69</RefSource>                <PMID Version="1">29576302</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2017 May;79(5):923-932</RefSource>                <PMID Version="1">28352985</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2013 Dec 13;8(12):e82236</RefSource>                <PMID Version="1">24349229</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2017 Jan 12;129(2):257-260</RefSource>                <PMID Version="1">27908881</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2005 Aug 15;65(16):7276-82</RefSource>                <PMID Version="1">16105816</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000813" MajorTopicYN="N">Anilides</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000944" MajorTopicYN="N">Antigens, Differentiation, B-Lymphocyte</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D066257" MajorTopicYN="N">Heparin-binding EGF-like Growth Factor</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000949" MajorTopicYN="N">Histocompatibility Antigens Class II</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015514" MajorTopicYN="N">Oncogene Proteins, Fusion</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011958" MajorTopicYN="N">Receptor, Epidermal Growth Factor</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D050614" MajorTopicYN="N">Sodium-Phosphate Cotransporter Proteins, Type IIb</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">AXL</Keyword>            <Keyword MajorTopicYN="N">HB-EGF</Keyword>            <Keyword MajorTopicYN="N">ROS1 fusion genes</Keyword>            <Keyword MajorTopicYN="N">cabozantinib</Keyword>            <Keyword MajorTopicYN="N">non-small lung cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30053332</ArticleId>            <ArticleId IdType="doi">10.1111/cas.13752</ArticleId>            <ArticleId IdType="pmc">PMC6172052</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>